Compare MobilEye Global Inc (MBLY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? MobilEye Global Inc trades at $7.1 (market cap $5.97B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MBLY | SYRE | |
|---|---|---|
Market Cap | $5.97B | $7.52B |
Volume | 6,124,531 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.33 | $108.92 |
52-Week Low | $6.56 | $22.18 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $4.53B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.02, up 2.63% with recent earnings beats but faces bearish technical signals and significant net losses. The stock shows strong institutional support with 57.7% analyst buy ratings and a $10.77 consensus target, yet profitability remains challenged with a -201.5% net margin. Recent news highlights ADAS business momentum and autonomous vehicle expansion opportunities.
The outlook presents a high-risk opportunity with potential upside from autonomous driving adoption, but investors face substantial execution risks and ongoing losses. Key catalysts include Porsche launch progress and robotaxi developments, while competitive pressures and cash flow volatility remain significant concerns for near-term performance.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
